Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of June 2020, with the announcement issued on June 19, 2020. The filing serves as a report of a material event regarding the company's oncology pipeline, specifically the regulatory review of an investigational drug.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory update regarding a specific drug application and does not contain financial statements or performance metrics.
Material Changes and Developments
- FDA Advisory Committee Meeting: The US Food and Drug Administration (FDA) will convene the Oncologic Drugs Advisory Committee (ODAC) to review GSK's Biologics License Application (BLA) for belantamab mafodotin.
- Meeting Details: The ODAC meeting is scheduled to be held virtually on July 14, 2020.
- Indication: The drug is under review for the treatment of patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
- Regulatory Status: Belantamab mafodotin received Breakthrough Therapy Designation in 2017 and Priority Review status in January 2020 based on the DREAMM-2 study.
Guidance, Outlook, and Risks
Management Commentary: Dr. Axel Hoos, Senior Vice President and Head of Oncology R&D, stated that the company believes belantamab mafodotin has significant potential for patients with limited treatment options and looks forward to the advisory committee meeting.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in the 2019 Form 20-F and potential impacts of the COVID-19 pandemic. The drug is not currently approved for use anywhere in the world.
Key Facts for Investor Verification
- Verify the outcome of the ODAC meeting scheduled for July 14, 2020, regarding belantamab mafodotin.
- Monitor the FDA's final decision on the Biologics License Application (BLA) following the advisory committee review.
- Review the DREAMM-2 clinical trial data published in The Lancet Oncology and presented at the 2020 ASCO annual meeting.
- Assess the potential impact of the COVID-19 pandemic on GSK's broader oncology pipeline and clinical trial operations.